CARM
Carisma Therapeutics Inc.Marquee-fund ownership over time
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Renaissance Technologies | Q3 2024 | Q1 2026 | → $0.04 | -96% |
| Millennium Management | Q3 2024 | Q2 2025 | → $0.18 | -82% |
| Two Sigma Investments | Q4 2024 | Q1 2025 | → $0.49 | -48% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Carisma Therapeutics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Oct 8, 2025 — the most recent Form 4 on file — not from today.
- Form 40001104659-25-097928Oct 8, 2025
- Form 40001104659-25-096740Oct 3, 2025
- Form 40001104659-25-007571Jan 30, 2025
- Form 40001104659-25-007565Jan 30, 2025
- Form 40001104659-24-113518Nov 1, 2024
- Form 40001104659-24-076988Jul 1, 2024
- Form 40001104659-24-076987Jul 1, 2024
- Form 40001104659-24-075721Jun 27, 2024
- Form 40001104659-24-075719Jun 27, 2024
- Form 40001104659-24-075717Jun 27, 2024
- Form 40001104659-24-075715Jun 27, 2024
- Form 40001104659-24-072978Jun 18, 2024
- Form 40001104659-24-072976Jun 18, 2024
- Form 40001104659-24-072975Jun 18, 2024
- Form 40001104659-24-042053Apr 1, 2024
Fundamentals
XBRL · Carisma Therapeutics Inc.Annual figures sourced directly from Carisma Therapeutics Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Carisma Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KDec 5, 2025
- 10-QQuarterly reportNov 12, 2025
- 8-KFORM 8-KOct 15, 2025
- 8-KFORM 8-KOct 9, 2025
- 8-KFORM 8-KSep 18, 2025
- S-4/ARegistration (M&A, amended)Aug 29, 2025
- 8-KFORM 8-KAug 29, 2025
- 8-KFORM 8-KAug 8, 2025
- 10-QQuarterly reportAug 7, 2025
- S-4Registration (M&A)Jul 21, 2025
- 8-KFORM 8-KJul 15, 2025
- DEF 14AProxy statementJul 7, 2025
- 8-KFORM 8-KJun 23, 2025
- 8-KFORM 8-KJun 12, 2025
- 10-QQuarterly reportMay 13, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q4 2024 | Q1 2025 | $0.94 | $0.49 | -48% |
| Millennium Management | Q3 2024 | Q2 2025 | $1.01 | $0.18 | -82% |
| Renaissance Technologies | Q3 2024 | Q1 2026 | $0.89 | $0.04 | -96% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.